Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)

Next Previous
Trial Profile

Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Denosumab (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Carcinoma; Early breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms GeparX

    • Most Recent Events

    • 09 Dec 2023 Results of Germline mutation status of BRCA1/2 and other breast cancer predisposition genes as predictive and prognostic biomarker, presented at the 46th Annual San Antonio Breast Cancer Symposium
    • 19 Sep 2023 Results (n=667) assessing RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer published in the Clinical Cancer Research
    • 01 Feb 2021 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top